Taysha Gene Therapies Inc
TSHA2.710USD
+0.080+3.04%
收盘 08/04, 16:00（美东）报价延迟15分钟
555.70M总市值
亏损市盈率 TTM
关于 Taysha Gene Therapies Inc 公司
Taysha Gene Therapies Inc 是一家临床阶段的生物技术公司，专注于推进腺相关病毒 (AAV) 基因疗法，用于治疗严重的中枢神经系统单基因疾病。该公司的主要临床项目 TSHA-102 正在开发中，用于治疗罕见的神经发育障碍雷特综合征。该公司正在 REVEALPhase I/II 青少年和成人临床试验中评估 TSHA-102，这是一项首次在人体中进行的开放标签、随机、剂量递增和剂量扩展的多中心研究，评估 TSHA-102 对 12 岁及以上患有雷特综合征的女性患者的安全性和初步疗效。该公司已获得临床阶段鞘内给药 AAV9 基因治疗项目 TSHA-120 的全球权利，用于治疗巨轴突神经病变 (GAN)。该公司的TSHA-120用于治疗GAN，获得了欧盟委员会的孤儿药称号。
公司简介
公司代码TSHA
公司名称Taysha Gene Therapies Inc
上市日期Sep 24, 2020
CEOMr. Sean Patrick Nolan
员工数量73
证券类型Ordinary Share
年结日Sep 24
公司地址3000 Pegasus Park Drive
城市DALLAS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编75247
电话12146120000
网址https://tayshagtx.com/
公司代码TSHA
上市日期Sep 24, 2020
CEOMr. Sean Patrick Nolan
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
362.05K
-38.56%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
250.13K
-30.27%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
362.05K
-38.56%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
250.13K
-30.27%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月28日 周一
更新时间: 7月28日 周一
持股股东
股东类型
持股股东
持股股东
占比
Manning (Paul B.)
10.16%
Avoro Capital Advisors LLC
7.94%
RTW Investments L.P.
7.46%
Fidelity Management & Research Company LLC
6.21%
Morgan Stanley & Co. LLC
5.81%
Other
62.42%
持股股东
持股股东
占比
Manning (Paul B.)
10.16%
Avoro Capital Advisors LLC
7.94%
RTW Investments L.P.
7.46%
Fidelity Management & Research Company LLC
6.21%
Morgan Stanley & Co. LLC
5.81%
Other
62.42%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
22.38%
Investment Advisor
21.43%
Hedge Fund
11.79%
Individual Investor
11.50%
Research Firm
6.38%
Venture Capital
4.65%
Corporation
0.61%
Sovereign Wealth Fund
0.58%
Bank and Trust
0.10%
Other
20.58%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
272
200.20M
79.47%
-19.12M
2025Q1
280
208.55M
85.47%
-19.89M
2024Q4
274
206.61M
100.79%
-12.49M
2024Q3
266
194.14M
94.73%
-23.74M
2024Q2
250
196.13M
97.09%
+4.27M
2024Q1
251
185.84M
99.33%
-1.52M
2023Q4
229
175.44M
93.86%
-4.17M
2023Q3
220
173.81M
93.01%
+41.64M
2023Q2
198
39.38M
61.40%
-9.23M
2023Q1
206
43.11M
72.56%
+244.20K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Manning (Paul B.)
25.60M
10.16%
+750.00K
+3.02%
May 30, 2025
Avoro Capital Advisors LLC
20.00M
7.94%
--
--
Mar 31, 2025
RTW Investments L.P.
18.79M
7.46%
+10.12M
+116.63%
Mar 31, 2025
Fidelity Management & Research Company LLC
15.63M
6.21%
-733.71K
-4.48%
Mar 31, 2025
Morgan Stanley & Co. LLC
14.64M
5.81%
-813.81K
-5.27%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
12.44M
4.94%
-91.46K
-0.73%
Mar 31, 2025
RA Capital Management, LP
10.87M
4.32%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
10.70M
4.25%
+250.00K
+2.39%
Mar 31, 2025
The Vanguard Group, Inc.
8.77M
3.48%
-135.84K
-1.53%
Mar 31, 2025
Invus Public Equities Advisors, LLC
6.51M
2.59%
-87.74K
-1.33%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Texas Capital Texas Small Cap Equity Index ETF
0.41%
iShares Micro-Cap ETF
0.09%
SPDR S&P Biotech ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Direxion Daily S&P Biotech Bull 3X Shares
0.04%
查看更多
iShares Neuroscience and Healthcare ETF
占比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.78%
Texas Capital Texas Small Cap Equity Index ETF
占比0.41%
iShares Micro-Cap ETF
占比0.09%
SPDR S&P Biotech ETF
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
Goldman Sachs Innovate Equity ETF
占比0.04%
iShares Biotechnology ETF
占比0.04%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
